Jia Wei
Impact in
- Infectious Diseases top 5%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Oncology top 5%
- CAR-T cell therapy research
Papers in
- Oncology 32
- CAR-T cell therapy research 21
- Cytokine Signaling Pathways and Interactions 4
- Hematology 10
- Acute Myeloid Leukemia Research 6
- Co-authors
- Jianfeng Zhou (17 shared papers)Liang Huang (13 shared papers)Xingcheng Yang (9 shared papers)Ling Ma (4 shared papers)Yi Xiao (3 shared papers)Fankai Meng (13 shared papers)Zhen Shang (1 shared paper)Jin Yin (1 shared paper)
- Journals
- Signal Transduction and Targeted Therapy (5 papers)Cancer Biology & Therapy (2 papers)Experimental Hematology and Oncology (2 papers)Cytotherapy (2 papers)Journal for ImmunoTherapy of Cancer (2 papers)
- Partner nations
- ChinaUnited StatesHong Kong
In The Last Decade
Jia Wei
62 papers receiving 1.8k citations
Jia Wei's Hit Papers
Peers
Comparison fields: 5 of 106
- Infectious Diseases 435
- Oncology 527
- Hematology 174
- Neurology 187
- Immunology 247
Countries citing papers authored by Jia Wei
This map shows the geographic impact of Jia Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jia Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jia Wei more than expected).
Fields of papers citing papers by Jia Wei
This network shows the impact of papers produced by Jia Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jia Wei. The network helps show where Jia Wei may publish in the future.
Co-authors
The 25 scholars most cited alongside Jia Wei, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 67 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial Hit paper breakdown → | 2020 | 359 |
| 2 | 2020 | 199 | |
| 3 | 2014 | 100 | |
| 4 | 2008 | 87 | |
| 5 | Deep insight into cytokine storm: from pathogenesis to treatment Hit paper breakdown → | 2025 | 85 |
| 6 | 2018 | 73 | |
| 7 | 2022 | 65 | |
| 8 | 2019 | 53 | |
| 9 | 2019 | 50 | |
| 10 | 2022 | 44 | |
| 11 | 2016 | 43 | |
| 12 | 2017 | 40 | |
| 13 | 2020 | 40 | |
| 14 | 2020 | 38 | |
| 15 | 2020 | 36 | |
| 16 | 2020 | 31 | |
| 17 | 2017 | 28 | |
| 18 | 2019 | 28 | |
| 19 | 2021 | 25 | |
| 20 | 2013 | 22 |
About Jia Wei
Jia Wei is a scholar working on Oncology, Hematology, Pathology and Forensic Medicine, Infectious Diseases and Genetics, having authored 67 papers that have together received 1.8k indexed citations. Recurring topics across this work include CAR-T cell therapy research (21 papers), Virus-based gene therapy research (8 papers), Lymphoma Diagnosis and Treatment (7 papers), Acute Myeloid Leukemia Research (6 papers), Immune Cell Function and Interaction (5 papers), COVID-19 Clinical Research Studies (4 papers), Viral Infectious Diseases and Gene Expression in Insects (4 papers) and Cytokine Signaling Pathways and Interactions (4 papers). The work is most often cited by research in Infectious Diseases (435 citations), Oncology (527 citations), Hematology (174 citations), Neurology (187 citations) and Immunology (247 citations). Jia Wei has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Jianfeng Zhou, Liang Huang, Xingcheng Yang, Ling Ma, Yi Xiao, Fankai Meng, Zhen Shang, Jin Yin, Jiayuh Lin and Chenglong Li. Their work appears in journals such as Signal Transduction and Targeted Therapy, Cancer Biology & Therapy, Experimental Hematology and Oncology, Cytotherapy and Journal for ImmunoTherapy of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.